BR0317586A - Compostos para normalização do ciclo sono/vigìlia - Google Patents

Compostos para normalização do ciclo sono/vigìlia

Info

Publication number
BR0317586A
BR0317586A BR0317586-3A BR0317586A BR0317586A BR 0317586 A BR0317586 A BR 0317586A BR 0317586 A BR0317586 A BR 0317586A BR 0317586 A BR0317586 A BR 0317586A
Authority
BR
Brazil
Prior art keywords
sleep
containing compound
compound
compounds
adenosine
Prior art date
Application number
BR0317586-3A
Other languages
English (en)
Inventor
Perry F Renshaw
Scott Lukas
Original Assignee
Mclean Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mclean Hospital Corp filed Critical Mclean Hospital Corp
Publication of BR0317586A publication Critical patent/BR0317586A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSTOS PARA NORMALIZAçãO DO CICLO SONO/VIGìLIA". A invenção provê métodos para normalização do ciclo sono/vigília de um mamífero por administração ao mamífero de um montante terapeuticamente eficaz de um composto contendo citidina, composto contendo citisina, composto contendo uridina, composto contendo creatina, composto contendo adenosina, ou composto de elevação de adenosina. Assim, os métodos descritos aqui podem aumentar o estado desperto, reduzir o cansaço ou fadiga durante o dia, e melhorar a qualidade sono. Os métodos da invenção podem também ser usados no tratamento de distúrbios do sono, como insónia, apnéia do sono, movimentos periódicos dos membros, síndrome das pernas inquietas, narcolepsia, e sonolência problemática, ou para aumentar a função cognitiva em indivíduos privados do sono. Citicolina é um exemplo de composto para uso nos métodos aqui descritos.
BR0317586-3A 2002-12-20 2003-12-17 Compostos para normalização do ciclo sono/vigìlia BR0317586A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43545702P 2002-12-20 2002-12-20
PCT/US2003/040450 WO2004058160A2 (en) 2002-12-20 2003-12-17 Compounds for the normalization of the sleep/wake cycle

Publications (1)

Publication Number Publication Date
BR0317586A true BR0317586A (pt) 2005-11-22

Family

ID=32682243

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317586-3A BR0317586A (pt) 2002-12-20 2003-12-17 Compostos para normalização do ciclo sono/vigìlia

Country Status (12)

Country Link
US (1) US20040176316A1 (pt)
EP (1) EP1589979A4 (pt)
JP (2) JP4717444B2 (pt)
CN (1) CN100563660C (pt)
AU (1) AU2003299715A1 (pt)
BR (1) BR0317586A (pt)
CA (1) CA2508995A1 (pt)
MX (1) MXPA05006781A (pt)
NO (1) NO20052987L (pt)
RU (1) RU2366428C2 (pt)
UA (1) UA88869C2 (pt)
WO (1) WO2004058160A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
JP4667041B2 (ja) * 2002-11-08 2011-04-06 ザ マクレーン ホスピタル コーポレーション タバコ依存症および離脱症状の治療用化合物
WO2005034874A2 (en) * 2003-10-08 2005-04-21 The Mclean Hospital Corporation Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
AU2004317087A1 (en) * 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
US20090215714A1 (en) * 2004-06-10 2009-08-27 Perry Renshaw Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder
EP1765075A4 (en) * 2004-06-10 2010-11-10 Mclean Hospital Corp PYRIMIDINES, IN PARTICULAR URIDINE, USED IN TREATMENTS ON PATIENTS WITH BIPOLAR DISORDERS
WO2006020703A1 (en) * 2004-08-11 2006-02-23 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
ES2615521T3 (es) * 2005-05-23 2017-06-07 Massachusetts Institute Of Technology Composiciones que contienen PUFA y métodos de uso de las mismas
TW200827367A (en) * 2006-10-26 2008-07-01 Kyowa Hakko Kogyo Kk A therapeutic agent for irritable bowel syndrome
ES2716226T3 (es) * 2007-11-16 2019-06-11 Int Ip Holdings Llc Composición energética comestible con un contenido bajo en cafeína
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
JP5426918B2 (ja) * 2009-04-20 2014-02-26 株式会社 伊藤園 ウリジンを含有する抗疲労剤又は体力向上剤
JP2011032232A (ja) * 2009-08-04 2011-02-17 Ito En Ltd 興奮抑制用又は鎮静用組成物及びこれを含む飲食品
JP5989319B2 (ja) 2011-10-06 2016-09-07 ライオン株式会社 睡眠の質改善剤
AU2013273263B2 (en) * 2012-06-04 2017-08-24 Pfizer Inc. Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders
JP6214628B2 (ja) * 2013-04-05 2017-10-18 ライオン株式会社 内服組成物
EP3056096B1 (de) * 2015-02-05 2019-07-24 Smart Sleep GmbH Verwendung eines Nahrungsergänzungsmittels enthaltend Kreatin zur Reduktion des natürlichen Schlafbedarfs oder zur schnelleren Anpassung der zirkadianen Rhythmik an neue Zeitzonen
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4048316A (en) * 1974-03-04 1977-09-13 Penn Nathar W Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning
US4115576A (en) * 1974-04-02 1978-09-19 Penn Nathar W Compositions and method of employing the same for inhibiting alcohol intoxication
US4027017A (en) * 1974-07-16 1977-05-31 Chugai Seiyaku Kabushiki Kaisha Method of treating alcoholism
IT1200589B (it) * 1985-02-14 1989-01-27 Gibipharma Spa Derivati naturali attivita farmagologica
JPS63208524A (ja) * 1987-02-25 1988-08-30 Nippon Oil & Fats Co Ltd 睡眠リズム改善剤
US7173017B1 (en) * 1987-10-28 2007-02-06 Wellstat Therapeutics Corporation Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
JPH0418034A (ja) * 1990-05-11 1992-01-22 Kanegafuchi Chem Ind Co Ltd 点眼組成物
US5635486A (en) * 1990-05-11 1997-06-03 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Ophthalmic composition comprising a sleep adjusting substance
PT100525B (pt) * 1991-05-29 1999-10-29 Abbott Lab Azaspiranos substituidos imunomodulares, seu uso e composicoes farmaceuticas que os contem
US5704361A (en) * 1991-11-08 1998-01-06 Mayo Foundation For Medical Education And Research Volumetric image ultrasound transducer underfluid catheter system
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
US5472958A (en) * 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
US5888532A (en) * 1996-08-16 1999-03-30 Pritsos; Chris A. Treatment of alcoholism and related disorders with (nicotinamide-adenine dinucleotide) phosphate derivatives
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
US5958896A (en) * 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
ES2478044T3 (es) * 1998-07-31 2014-07-18 Massachusetts Institute Of Technology Uso de uridina en combinación con colina para el tratamiento de trastornos neurológicos
DE19929995B4 (de) * 1999-06-30 2004-06-03 Skw Trostberg Ag Verwendung von Kreatin und/oder Kreatin-Derivaten zur Behandlung von Befindlichkeitsstörungen bei Frauen
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
ES2170649B1 (es) * 2000-03-29 2003-06-16 Ferrer Int Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline

Also Published As

Publication number Publication date
NO20052987L (no) 2005-08-29
JP2006513214A (ja) 2006-04-20
RU2366428C2 (ru) 2009-09-10
NO20052987D0 (no) 2005-06-17
AU2003299715A1 (en) 2004-07-22
AU2003299715A8 (en) 2004-07-22
CA2508995A1 (en) 2004-07-15
EP1589979A4 (en) 2009-04-01
RU2005122934A (ru) 2006-01-20
CN1750833A (zh) 2006-03-22
US20040176316A1 (en) 2004-09-09
EP1589979A2 (en) 2005-11-02
WO2004058160A3 (en) 2005-03-31
MXPA05006781A (es) 2005-09-30
JP2011102319A (ja) 2011-05-26
UA88869C2 (ru) 2009-12-10
WO2004058160A2 (en) 2004-07-15
JP4717444B2 (ja) 2011-07-06
CN100563660C (zh) 2009-12-02

Similar Documents

Publication Publication Date Title
BR0317586A (pt) Compostos para normalização do ciclo sono/vigìlia
CY1109079T1 (el) Συνθεσεις που περιλαμβανουν μονταφινιλη για την θεραπεια διαταραχης ελλειψης προσοχης υπερδραστικοτητας
ES2165878T3 (es) Utilizacion del modafinil para el tratamiento de las apneas del sueño y trastornos de ventilacion de origen central.
CY1105729T1 (el) Παραγοντες με σχετιζομενη με σεροτονινη δραση για την αντιμετωπιση για υπνικη απνοια
BR0315846A (pt) Tratamento farmacológico para apnéia do sono
MEP35308A (en) COMPOUNDS SPECIFIC TO ADENOSINE A1, A2a, AND A3 RECEPTOR AND USES THEREOF
PT1261333E (pt) Utilizacao de topiramato para o tratamento e diagnostico de transtorno do sono relacionado com a respiracao e meios para realizar o metodo e o diagnostico
HUP0101645A2 (hu) Riluzol és L-DOPA kombinációi a Parkinson kór kezelésére
BR0307041A (pt) Corpos de fosfolipìdio e uso dos mesmos no tratamento de doenças inflamatórias e autoimunes
ATE421313T1 (de) Verwendung einer dihydrochalcon-reichen phenolischen fraktion für eine kosmetische behandlung
PT1030667E (pt) Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
NO20005757D0 (no) Cabergolin og pramipexol - nye anvendelser og kombinasjoner
EA200870108A1 (ru) Мутанты фсг
DE602004025683D1 (de) Therapeutische zubereitung für autoimmune erkrankungen
CN208823097U (zh) 一种固定效果好的骨科固定装置
Knuckles et al. Yellow nail syndrome in association with sleep apnea.
CN2368482Y (zh) 防止打鼾器
SU1326273A1 (ru) Способ лечени вегетативных полиневропатий
WO2008077127A3 (en) Use of modafinil to treat restless leg syndrome
Evans et al. Is it migraine or cluster?
MX2021016090A (es) Lemborexant para el tratamiento de problemas del sueño.
ITPD980294A1 (it) Struttura di capo traspirante da indossare per migliorare il comfort del corpo umano.
BR0314945A (pt) Uso de antagonistas de receptor 5-ht2 para tratamento de distúrbios de sono
KR940000088A (ko) 지압용 고무장갑
ES1042492U (es) Nueva almohadilla para tratar y evitar afecciones cutaneas.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.